After gaining a BSc in Biochemistry at the University of Edinburgh, UK, Sreten trained as an endocrinologist at Imperial College, London, UK. His PhD dealt with the role of the pituitary gland in the pathogenesis of obesity and type II (non-insulin dependent) diabetes, using animal models such as the genetically obese ob/ob (now lep/lep) mouse, and working in conjunction with Beecham Pharmaceuticals Limited (now, after several mergers and acquisitions, GlaxoSmithKline plc). Sreten subsequently worked at the University of Sussex, UK, on the mode of action of pituitary growth hormone and the mechanisms of glucose-stimulated insulin secretion.
His business career includes three years as product manager for immunodiagnostics with the UK subsidiary of a German healthcare multinational, Boehringer Mannheim, now owned by Roche, and six years as an independent biomedical technology analyst with Cistron of Coventry, UK. At Boehringer, Sreten's product range consisted of the Enzymun System (ES) coated-tube enzyme immunoassay kits and associated instrumentation. These products were launched in the UK under his direction, have been a considerable success in commercial terms, and were among the first automated nonisotopic immunoassays on the market. The Enzymun System range has now been superseded by the Elecsys range. While Biophoenix was based at Coventry University, Sreten also held a post as lecturer in the Faculty of Health and Life Sciences.
As an independent consultant, Sreten has specialised in immunodiagnostics, DNA-based tests, and the applications of biotechnology to human therapeutics. His publications include a number of market and technology studies in these areas for clients such as Drug and Market Development Inc (part of Informa PLC), Financial Times Healthcare, Frost & Sullivan, PJB Publications (now also part of Informa PLC), and Business Insights (formerly Reuters Business Insights). Subjects covered so far include recombinant pharmaceuticals, drug delivery, DNA diagnostics, immunodiagnostics, cancer diagnostics, immune system diagnostics, angiogenesis-based therapeutics, oligonucleotide-based therapeutics, gene therapy, stem cells, pharmacogenomics, and reports on drug targets such as kinases and transporters.
Sreten is a member of the UK Society
for Endocrinology (by publication) and the
American Association for Clinical Chemistry (AACC).
